- Trial Phase
- Phase 3
- Time to Market
- If LEVEL Phase 3 data is positive (Aug 2026), Tenax would need to complete a second registrational study (LEVEL-2) and file an NDA. Realistic best-case US approval would be 2028-2029, assuming positive results and a standard FDA review cycle.
- Why 9/10
- The single next hard, dated catalyst is the Phase 3 LEVEL topline data readout in August 2026, with results presented as a Late-Breaking Clinical Science session at ESC Congress 2026 (Aug 28-31). Tenax is effectively a single-asset company; oral levosimendan (TNX-103) drives nearly all of TENX's enterprise value, making this a make-or-break binary event within ~6 weeks.
The Phase 3 LEVEL topline readout in August 2026 is a make-or-break binary catalyst. Positive data could unlock a ~$2B+ market opportunity as the first approved therapy for PH-HFpEF, while a miss would likely devastate the stock. With a strong cash runway (~$118.8M through Q1 2028), no near-term dilution risk exists. This is a pure binary options-style biotech setup — size accordingly.
Price Chart
Executive Summary
Levosimendan is a well-characterized cardiovascular drug already approved in IV form in 60+ countries outside the US (branded Simdax by Orion) for acute decompensated heart failure. Tenax Therapeutics (TENX) is developing an oral formulation (TNX-103) for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) — a severe condition with zero FDA-approved therapies and a large unmet need. The Phase 3 LEVEL trial completed enrollment at ~230 patients and topline results are due in August 2026, with a late-breaking presentation at ESC Congress 2026. Analysts are overwhelmingly bullish (Strong Buy consensus, mean PT ~$33.88 vs ~$13.29), and major institutions (Janus Henderson, Point72, FMR, Adage Capital) have been accumulating shares. With $118.8M cash funding operations through Q1 2028, the company is well-capitalized into this binary catalyst.
How It Works
Levosimendan is a "calcium sensitizer" and blood-vessel dilator (inodilator). It makes the heart pump more forcefully without increasing the heart's calcium load (which can be dangerous with other heart-failure drugs), while also relaxing blood vessels to reduce pressure on the heart and lungs. Its active metabolite lasts for days, giving a sustained effect.
Trial Status
The Phase 3 LEVEL program includes two registrational studies. The first (LEVEL, NCT05983250) enrolled over 230 patients and topline data is expected in August 2026, presented at ESC Congress 2026. The second (LEVEL-2) was announced in March 2025 and recruitment is underway. Phase 2 data previously demonstrated that IV levosimendan improved exercise hemodynamics and exercise capacity (6-minute walk test) in PH-HFpEF patients.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 LEVEL topline data readout — August 2026
- Late-Breaking Clinical Science presentation at ESC Congress 2026 — Aug 28-31, Munich
- LEVEL-2 Phase 3 trial enrollment and interim updates
- Potential NDA filing if LEVEL data and LEVEL-2 data are positive
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Tenax Therapeutics, Inc. Press Release TENX ·Originating report